Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 1-Year High - Here's What Happened

Key Points

• Aurinia Pharmaceuticals shares reached a new 52-week high at $12.90, following strong trading volume and a previous close of $12.30.
• Wall Street analysts have a consensus rating of "Buy" for Aurinia, with price targets ranging from $9.00 to $17.00, indicating potential growth.
• Recent insider transactions include Director Kevin Tang acquiring 1,000,000 shares, increasing his total ownership substantially and reflecting confidence in the company's future.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP shares reached a new 52-week high on Thursday . The company traded as high as $12.90 and last traded at $12.89, with a volume of 1330837 shares. The stock had previously closed at $12.30.

Wall Street Analysts Forecast Growth

AUPH has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $13.00.

Aurinia Pharmaceuticals Price Performance

The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 25.49 and a beta of 1.26. The company has a 50-day moving average price of $11.28 and a 200-day moving average price of $9.18. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). The firm had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Activity

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 1,000,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was acquired at an average cost of $10.12 per share, for a total transaction of $10,120,000.00. Following the transaction, the director owned 11,029,500 shares of the company's stock, valued at $111,618,540. This trade represents a 9.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders purchased 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of large investors have recently bought and sold shares of AUPH. Ameriprise Financial Inc. boosted its position in Aurinia Pharmaceuticals by 249.5% during the 4th quarter. Ameriprise Financial Inc. now owns 37,796 shares of the biotechnology company's stock worth $339,000 after acquiring an additional 26,981 shares during the last quarter. Cetera Investment Advisers boosted its position in Aurinia Pharmaceuticals by 3.2% during the 4th quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock worth $580,000 after acquiring an additional 2,000 shares during the last quarter. Deutsche Bank AG boosted its position in Aurinia Pharmaceuticals by 54.8% during the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock worth $1,283,000 after acquiring an additional 50,575 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Aurinia Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock worth $685,000 after acquiring an additional 2,887 shares during the last quarter. Finally, Millennium Management LLC boosted its position in Aurinia Pharmaceuticals by 49.9% during the 4th quarter. Millennium Management LLC now owns 87,421 shares of the biotechnology company's stock worth $785,000 after acquiring an additional 29,096 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.